Trial Profile
Phase I and II clinical trials of multiple immunotherapies, including nivolumab and ipilimumab, to treat patients with acute myeloid leukaemia, chronic lymphocytic leukaemia, chronic myeloid leukaemia, myelodysplastic syndromes and myelofibrosis.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2014
Price :
$35
*
At a glance
- Drugs Immunotherapies (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 13 Oct 2014 New trial record